Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 28,000 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the sale, the insider owned 118,234 shares in the company, valued at $16,273,727.76. This represents a 19.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Johanna Mercier also recently made the following trade(s):

• On Monday, June 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $123.92, for a total transaction of $371,760.00.

Gilead Sciences Stock Up 3.3%

Shares of NASDAQ:GILD opened at $143.44 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The company has a market capitalization of $177.86 billion, a PE ratio of -53.72 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The company has a fifty day moving average of $130.69 and a 200-day moving average of $136.46.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.Gilead Sciences’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the business posted $2.01 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post -0.53 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Analyst Ratings Changes

Several research analysts have recently issued reports on GILD shares. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research report on Wednesday, August 5th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the company from $133.00 to $155.00 in a research note on Monday, July 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Daiwa Securities Group decreased their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Twenty-four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $158.04.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in GILD. Brighton Jones LLC lifted its holdings in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new position in Gilead Sciences during the 4th quarter valued at about $215,000. Sivia Capital Partners LLC increased its holdings in Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares in the last quarter. Ieq Capital LLC increased its holdings in Gilead Sciences by 12.0% during the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after purchasing an additional 12,705 shares in the last quarter. Finally, Diversify Advisory Services LLC raised its stake in shares of Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after purchasing an additional 674 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: A federal appeals court blocked companies from importing and selling cheaper foreign versions of Biktarvy in the United States. The ruling helps protect revenue from Gilead’s leading HIV treatment and removes a potential competitive and pricing threat. Gilead stock court ruling on Biktarvy imports
• Positive Sentiment: Gilead’s HIV franchise remains the primary growth engine. Biktarvy continues to lead treatment, while the newer Yeztugo product and additional pipeline programs could expand the company’s prevention and treatment opportunities. Is Gilead’s Expanding HIV Portfolio a Growth Catalyst?
• Positive Sentiment: Commentary from The Motley Fool highlighted Gilead as an underappreciated healthcare turnaround story, citing double-digit quarterly revenue growth, strong HIV sales, acquisitions, and an expanding oncology portfolio. This supports investor optimism about longer-term diversification beyond HIV. Gilead Sciences turnaround story
• Neutral Sentiment: Gilead is participating in a highly competitive antibody-drug conjugate oncology market. The company’s technology and patent position may create future opportunities, but the landscape also involves substantial competition and development risk. Cancer and antibody-drug conjugates patent landscape
• Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares worth approximately $3.85 million. Because the transaction occurred under a pre-arranged Rule 10b5-1 plan, it is a limited signal about management’s outlook, though insider selling can still weigh modestly on sentiment.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.